Akebia Therapeutics, Inc. (AKBA) Income Statement Analysis

See more : Emperor Metals Inc. (AUOZ.CN) Income Statement Analysis – Financial Results

Complete financial analysis of Akebia Therapeutics, Inc. (AKBA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Akebia Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Akebia Therapeutics, Inc. (AKBA)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.akebia.com

About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	194.62M	292.60M	213.58M	295.31M	335.00M	207.74M	177.98M	1.54M	0.00	0.00	0.00	0.00
Cost of Revenue	74.15M	84.80M	153.39M	295.91M	145.34M	7.69M	617.00K	115.79M	96.00K	23.26M	0.00	0.00
Gross Profit	120.47M	207.81M	60.18M	-601.00K	189.67M	200.06M	177.37M	-114.25M	-96.00K	-23.26M	0.00	0.00
Gross Profit Ratio	61.90%	71.02%	28.18%	-0.20%	56.62%	96.30%	99.65%	-7,443.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	63.08M	129.11M	147.85M	218.49M	322.97M	291.07M	230.89M	115.79M	43.02M	25.40M	10.78M	5.63M
General & Administrative	0.00	141.87M	177.65M	157.36M	152.98M	87.13M	27.01M	22.21M	18.50M	12.54M	5.15M	2.89M
Selling & Marketing	100.23M	-3.18M	174.16M	153.95M	149.46M	87.06M	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	100.23M	141.87M	174.16M	153.95M	149.46M	87.06M	27.01M	22.21M	18.50M	12.54M	5.15M	2.89M
Other Expenses	3.42M	-12.54M	3.49M	3.41M	3.53M	6.24M	204.00K	-188.00K	287.00K	700.00K	1.05M	1.97M
Operating Expenses	166.73M	270.99M	325.50M	375.84M	475.95M	378.20M	257.90M	138.00M	61.51M	37.94M	15.93M	8.52M
Cost & Expenses	240.88M	355.78M	478.90M	671.75M	621.29M	385.88M	257.90M	138.00M	61.51M	37.94M	15.93M	8.52M
Interest Income	0.00	15.69M	19.95M	8.92M	2.19M	6.15M	2.80M	901.00K	0.00	0.00	0.00	1.64M
Interest Expense	6.03M	15.69M	19.94M	8.87M	1.40M	6.15M	0.00	0.00	510.00K	206.00K	703.57K	0.00
Depreciation & Amortization	37.63M	35.28M	36.13M	33.59M	36.42M	2.42M	617.00K	296.00K	96.00K	49.00K	1.28K	39.16K
EBITDA	-6.87M	-43.26M	-225.96M	-341.00M	-247.64M	-178.09M	-76.06M	-136.16M	-61.42M	-37.89M	-12.46M	-6.55M
EBITDA Ratio	-3.53%	-15.84%	-124.23%	-127.47%	-85.46%	-85.75%	-44.55%	-8,870.62%	0.00%	0.00%	0.00%	0.00%
Operating Income	-46.26M	-63.18M	-265.32M	-376.44M	-286.29M	-178.14M	-79.92M	-136.46M	-61.51M	-37.94M	-15.93M	-8.52M
Operating Income Ratio	-23.77%	-21.59%	-124.23%	-127.47%	-85.46%	-85.75%	-44.90%	-8,889.90%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	-5.67M	-13.45M	-17.52M	-5.63M	-2.00K	6.24M	3.00M	713.00K	497.00K	906.00K	2.77M	327.00K
Income Before Tax	-51.93M	-92.56M	-282.84M	-383.46M	-286.29M	-171.90M	-76.91M	-135.75M	-60.72M	-37.03M	-13.17M	-8.20M
Income Before Tax Ratio	-26.68%	-31.63%	-132.43%	-129.85%	-85.46%	-82.75%	-43.21%	-8,843.45%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	13.45M	-37.97M	-33.59M	-6.63M	-28.34M	-2.80M	-901.00K	-510.00K	-206.00K	1.75M	1.60M
Net Income	-51.93M	-106.01M	-244.87M	-349.87M	-279.66M	-171.90M	-76.91M	-135.75M	-60.72M	-37.03M	-13.17M	-8.20M
Net Income Ratio	-26.68%	-36.23%	-114.65%	-118.48%	-83.48%	-82.75%	-43.21%	-8,843.45%	0.00%	0.00%	0.00%	0.00%
EPS	-0.28	-0.58	-1.48	-2.53	-2.36	-1.47	-1.77	-3.60	-2.29	-2.40	-0.68	-0.81
EPS Diluted	-0.28	-0.58	-1.48	-2.53	-2.36	-1.47	-1.77	-3.60	-2.29	-2.40	-0.68	-0.81
Weighted Avg Shares Out	187.47M	182.78M	165.95M	138.46M	118.40M	116.89M	43.50M	37.72M	26.47M	15.41M	19.27M	10.13M
Weighted Avg Shares Out (Dil)	187.47M	182.78M	165.95M	138.46M	118.40M	116.89M	43.50M	37.72M	26.47M	15.41M	19.27M	10.13M

Akebia Therapeutics Provides Update on Form 10-Q Filing

August 10, 2023prnewswire.com

Akebia announces late filing of its second quarter earnings and Form 10-Q Akebia reaffirms 2023 net product revenue guidance of $175 - $180 million Akebia believes its cash resources as of June 30, 2023 will be sufficient to fund its...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2023prnewswire.com

CAMBRIDGE, Mass. , Aug. 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted Ellen Snow, Akebia's newly-hired Senior Vice President, Chief Financial Officer...

Akebia Therapeutics to Present at the H.C. Wainwright Kidney Conference

July 19, 2023prnewswire.com

CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a...

Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023

July 18, 2023prnewswire.com

CAMBRIDGE, Mass. , July 18, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia completed an End of Dispute...

Best Stocks For Beginners with Little Money: How To Trade Penny Stocks

July 10, 2023pennystocks.com

There are so many new traders and investors entering the stock market today. But if you're brand new, you might not have a lot of money to invest or don't want to risk a whole lot while you're learning how...

Pocket Change, Big Gains: 3 Penny Stocks Ready to Boom

July 6, 2023investorplace.com

Investors seeking high-growth opportunities often turn their attention to penny stocks, which may have the potential to deliver substantial returns. The three potential high return penny stocks listed in the article possess the ingredients for explosive growth.